Prognostic Risk Systems for Therapeutic Decision Making in Myelodysplastic Syndromes
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: July 17, 2015
Expiration Date: July 17, 2016
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Consequently, risk evaluation is a critical component of decision-making in the treatment of MDS. However, with only some 13,000 people in the United States diagnosed annually with MDS, community-based clinicians see relatively few patients with this disorder in their practice and thus may lack requisite experience navigating evidence-based risk evaluation and corresponding clinical management strategies such as those recommended in NCCN Guidelines® for MDS. These guidelines and consensus recommendations are continuously updated to reflect the wealth of clinical data being generated, and are essential for establishing which diagnosis, risk evaluation, and response assessment tests should be performed, as well as which regimens and supportive care strategies are preferred based on an individual patient’s risk factors and response to treatment throughout the life cycle of the disease. Ultimately, remaining informed regarding the development of newer treatments and the refinement of current treatment modalities is an essential part of ensuring improved patient outcomes while reducing associated side effects as this not only impacts the duration of life but also the quality of life of MDS patients.
Join world-leading Managing MDS team experts Stuart Goldberg, MD, associate clinical professor of medicine at the John Theurer Cancer Center in Hackensack, New Jersey, and Peter Greenberg, MD, professor of medicine (hematology), director of the Stanford MDS Center at the Stanford University Cancer Center, coordinator of the International Working Group for the Prognosis of MDS (IWG-PM), and chair of the NCCN Myelodysplastic Syndromes Practice Guidelines Panel, in a case-based discussion evaluating the prognostic features of individual MDS patients including the use of morphological classification, as well as various risk systems including one of those most widely used in the United States today, the Revised International Prognostic Scoring System (IPSS-R), to determine MDS patients’ risk category, associated prognosis, and recommended treatment strategies.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in MDS.
Upon completion of this educational activity, participants should be able to:
- Define prognostic features of MDS
- Summarize goals of the IPSS-R classification system and risk categorization
- Identify how outcomes for patients with MDS can be enhanced through the use of individualized risk-adapted strategies for treatment that take into account treatment goals based on a patient’s risk status
Prognostic Risk Systems for Therapeutic Decision Making in Myelodysplastic Syndromes – Stuart Goldberg, MD, and Peter Greenberg, MD
Instructions for Participation and Credit
This activity is eligible for credit through July 17, 2016. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Stuart L. Goldberg, MD
Division of Leukemia
John Theurer Cancer Center
Hackensack, New Jersey
Dr. Stuart Goldberg received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center. He completed his internal medicine residency and his hematology-oncology fellowship at George Washington University Medical Center. He also completed a bone marrow transplantation fellowship at Fred Hutchinson Cancer Research Center. Dr. Goldberg is a part of the Division of Leukemia, John Theurer Cancer Center in Hackensack, New Jersey.
Dr. Goldberg specializes in medical oncology and leukemia, and is board certified in medical oncology, hematology and internal medicine. He is a member of the American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the Myelodysplastic Foundation, among others. Dr. Goldberg specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation.
Peter Greenberg, MD
Professor of Medicine (Hematology)
Stanford University Cancer Center
Palo Alto, California
Dr. Peter Greenberg’s laboratory research focuses on evaluating molecular abnormalities in myelodysplastic syndromes (MDS) with specific interest in gene expression profiling of marrow stem and progenitor cells using RNA Seq and microarray methodologies and proteomic analysis of aberrant antigen expression in plasma. As director of the Stanford MDS Center, his clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. Dr. Greenberg is coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the IPSS-R and is now evaluating the impact of molecular mutations on this risk-based prognostic system. He is also chair of the NCCN Practice Guidelines Panel for MDS.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-017-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Stuart Goldberg has received honoraria related to speakers’ bureau activities from ARIAD, Bristol-Myers Squibb Company, and Novartis. He has received grant support related to research activities from ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer Inc. Dr. Goldberg has been employed by COTA (Cancer Outcomes Tracking Analysis).
Dr. Peter Greenberg has received honoraria related to formal advisory activities from Novartis AG.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Goldberg has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Greenberg has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Goldberg has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Greenberg has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.